Lpad LyumjevLyumjev Insulin for Adolescents With Type 1 Diabetes

This study focuses on improving insulin treatment for adolescents with Type 1 Diabetes (T1D) by using a faster-acting insulin called Lyumjev. The aim is to determine if Lyumjev can better manage blood sugar levels compared to the commonly used insulins, Humalog or Novolog, when used in an automated insulin delivery system. This is important because maintaining blood sugar within the target range can help prevent complications associated with diabetes and improve the quality of life for young patients. Participants in the study first go through an optimization phase with the insulin they usually use, either Humalog or Novolog, to establish a controlled baseline. Then, in a randomized phase, some participants switch to Lyumjev using a calculated conversion factor, while others continue with their usual insulin. The study observes how well each insulin controls blood sugar levels by comparing the time spent in the target range during the randomized phase to the baseline period. This approach helps identify any differences in effectiveness between the insulins, potentially offering a better treatment option for managing T1D.